DeepMed Research

UNIVERSITY OF CINCINNATI

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1819-01-01

Employees: 5.9K

Market Cap: -

Website: https://www.uc.edu/

Clinical Trials

Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension

Phase 2

Completed

Conditions: Pulmonary Arterial Hypertension
Sarcoidosis

Interventions: Drug: Placebo
Drug: Bosentan

First Posted Date: 2007-12-27

Last Posted Date: 2013-04-12

Lead Sponsor: University of Cincinnati

Target Recruit Count: 43

Registration Number: NCT00581607

Locations: 🇺🇸
Mount Sinai, New York, New York, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 1 locations

The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome

Phase 2

Withdrawn

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Erlotinib

First Posted Date: 2007-12-10

Last Posted Date: 2019-11-25

Lead Sponsor: University of Cincinnati

Registration Number: NCT00570375

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Nutrient Levels Alter Transplant Outcome

Not Applicable

Completed

Conditions: Chronic Renal Disease

Interventions: Dietary Supplement: Coromega and Arginine
Dietary Supplement: Arginine and canola oil

First Posted Date: 2007-11-19

Last Posted Date: 2007-11-19

Lead Sponsor: University of Cincinnati

Target Recruit Count: 54

Registration Number: NCT00560014

Locations: 🇺🇸
Duke University School Of Medicine, Durham, North Carolina, United States
🇺🇸
Washington Hospital, Washington, District of Columbia, United States

Omega-3 Fatty Acid Status in Morbid Obesity Before and After Surgical Treatment

Withdrawn

Conditions: Morbid Obesity
Cardiovascular Disease
Fatty Acid Levels

Interventions: Procedure: Bariatric Surgery

First Posted Date: 2007-11-15

Last Posted Date: 2016-06-13

Lead Sponsor: University of Cincinnati

Registration Number: NCT00558532

Locations: 🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States

Use of Armodafinil for Fatigue in Sarcoidosis

Phase 2

Completed

Conditions: Sarcoidosis
Sleepiness
Fatigue

Interventions: Drug: Placebo
Drug: Armodafinil

First Posted Date: 2007-11-08

Last Posted Date: 2015-05-27

Lead Sponsor: University of Cincinnati

Target Recruit Count: 20

Registration Number: NCT00555347

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults

Phase 4

Completed

Conditions: Bipolar Disorder
Alcohol Abuse

Interventions: Drug: quetiapine and placebo
Drug: Quetiapine and Topiramate

First Posted Date: 2007-10-29

Last Posted Date: 2017-05-23

Lead Sponsor: University of Cincinnati

Target Recruit Count: 56

Registration Number: NCT00550394

Locations: 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

Phase 1

Completed

Conditions: Hepatitis C
HIV Infections

Interventions: Drug: Efavirenz
Drug: Emtricitabine/Tenofovir disoproxil fumarate

First Posted Date: 2007-10-17

Last Posted Date: 2014-08-12

Lead Sponsor: University of Cincinnati

Target Recruit Count: 18

Registration Number: NCT00545558

Locations: 🇺🇸
General Clinical Research Center (GCRC), OH site, Cincinnati, Ohio, United States
🇺🇸
Virginia Commonwealth University, School of Medicine, Richmond, Virginia, United States

Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease

Phase 4

Completed

Conditions: Parkinson's Disease
Gait Impairment

Interventions: Drug: Methylphenidate (MPD)
Drug: Placebo

First Posted Date: 2007-09-10

Last Posted Date: 2015-04-22

Lead Sponsor: University of Cincinnati

Target Recruit Count: 23

Registration Number: NCT00526630

Locations: 🇺🇸
University Neurology-Movement Disorders Clinic, Cincinnati, Ohio, United States

Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: High Dose Fish Oil
Drug: Low Dose Fish Oil

First Posted Date: 2007-08-06

Last Posted Date: 2016-05-27

Lead Sponsor: University of Cincinnati

Target Recruit Count: 20

Registration Number: NCT00511810

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Effects of a Ketogenic Diet on Body Weight and Cardiovascular Risk Factors

Phase 1

Completed

Conditions: Obesity

First Posted Date: 2007-07-10

Last Posted Date: 2007-07-10

Lead Sponsor: University of Cincinnati

Target Recruit Count: 103

Registration Number: NCT00498394

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy